We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Humana (HUM - Free Report) is a health care plan provider in the United States. The company provides health insurance benefits under Health Maintenance Organization, Private Fee-For-Service, and Preferred Provider Organization plans.
Analysts have taken a bearish stance on the company’s earnings outlook, landing it into a Zacks Rank #5 (Strong Sell).
Image Source: Zacks Investment Research
In addition, the company currently resides in the Zacks Medical – HMOs industry, which is currently ranked in the bottom 14% of all Zacks industries. Let’s take a closer look at a few other aspects of the company.
Humana
HUM shares have struggled to find their footing over the last year, losing nearly -29% in value and widely underperforming relative to the S&P 500. Shares faced notably strong selling pressure following its latest quarterly release, with the company falling short of the Zacks Consensus EPS estimate by 57%.
Image Source: Zacks Investment Research
The results were hampered by an additional increase in Medicare Advantage medical cost trends, causing the company to give ‘soft’ initial guidance for its FY24. The results snapped a streak of positive EPS surprises, with investors reacting negatively in response.
Image Source: Zacks Investment Research
The company’s profitability is forecasted to take a sizable hit in its current year (FY24), with the $16.05 Zacks Consensus EPS estimate representing a pullback of -38% from FY23. Shares presently trade at a 20.3X forward 12-month earnings multiple, above the five-year median and the respective Zacks industry average.
The stock carries a Style Score of ‘D’ for Value.
Image Source: Zacks Investment Research
Bottom Line
Negative earnings estimate revisions from analysts stemming from increased costs paint a challenging picture for the company’s shares in the near term.
Humana (HUM - Free Report) is a Zacks Rank #5 (Strong Sell), indicating that analysts have taken a bearish stance on the company’s earnings outlook.
For those seeking strong stocks, a great idea would be to focus on stocks carrying a Zacks Rank #1 (Strong Buy) or a Zacks Rank #2 (Buy) – these stocks sport a notably stronger earnings outlook paired with the potential to deliver explosive gains in the near term.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Bear of the Day: Humana (HUM)
Humana (HUM - Free Report) is a health care plan provider in the United States. The company provides health insurance benefits under Health Maintenance Organization, Private Fee-For-Service, and Preferred Provider Organization plans.
Analysts have taken a bearish stance on the company’s earnings outlook, landing it into a Zacks Rank #5 (Strong Sell).
Image Source: Zacks Investment Research
In addition, the company currently resides in the Zacks Medical – HMOs industry, which is currently ranked in the bottom 14% of all Zacks industries. Let’s take a closer look at a few other aspects of the company.
Humana
HUM shares have struggled to find their footing over the last year, losing nearly -29% in value and widely underperforming relative to the S&P 500. Shares faced notably strong selling pressure following its latest quarterly release, with the company falling short of the Zacks Consensus EPS estimate by 57%.
Image Source: Zacks Investment Research
The results were hampered by an additional increase in Medicare Advantage medical cost trends, causing the company to give ‘soft’ initial guidance for its FY24. The results snapped a streak of positive EPS surprises, with investors reacting negatively in response.
Image Source: Zacks Investment Research
The company’s profitability is forecasted to take a sizable hit in its current year (FY24), with the $16.05 Zacks Consensus EPS estimate representing a pullback of -38% from FY23. Shares presently trade at a 20.3X forward 12-month earnings multiple, above the five-year median and the respective Zacks industry average.
The stock carries a Style Score of ‘D’ for Value.
Image Source: Zacks Investment Research
Bottom Line
Negative earnings estimate revisions from analysts stemming from increased costs paint a challenging picture for the company’s shares in the near term.
Humana (HUM - Free Report) is a Zacks Rank #5 (Strong Sell), indicating that analysts have taken a bearish stance on the company’s earnings outlook.
For those seeking strong stocks, a great idea would be to focus on stocks carrying a Zacks Rank #1 (Strong Buy) or a Zacks Rank #2 (Buy) – these stocks sport a notably stronger earnings outlook paired with the potential to deliver explosive gains in the near term.